Abstract:Prostate cancer stands as the foremost cause of cancer-related deaths among men in the United States, with the primary treatment being androgen receptor (AR) antagonists relying on current androgen signaling knowledge. Most of this knowledge is derived from next-generation sequencing experiments, but the oversight of splice variants and highly similar sequences in multiple loci can hinder a comprehensive understanding. In an effort to unveil the complete androgen receptor transcriptional program, we employed a novel sequencing analysis protocol. Using a R1881-LNCaP model, we identified 212 upregulated and 92 downregulated genes, of which a notable one-third (68 upregulated and 39 downregulated) had not been previously associated with androgen. Among these novel transcripts, 5.6% lacked splice variants, while 16.3% exhibited one or more splice variants, including 3.8% from seven unique gene families. Recognized androgen-regulated genes, such as ORM1, STEAP4, NPPC, ORM2, and KLK3, were validated as upregulated, while GRB10, FN1, PPFIA2, and PLA2G2A were confirmed as downregulated in this in-vitro model. Utilizing chromatin immunoprecipitation-sequencing (ChIP-seq) data, we found that 13% of the genes contained at least one androgen response element within 5 kb upstream or downstream. Further validation through real-time PCR confirmed the expression levels of 90% of the selected genes (18). Ingenuity Pathway Analysis revealed two major regulators (ESRRA and ARFGEF2) in causal networks likely interacting with the novel genes. Intriguingly, 57.1% of ESRRA-involved genes contained at least one ESRRA binding site in a ChIP-seq dataset. Although ESRRA is known to activate androgen biosynthesis in castration-resistant prostate cancer, its interaction with AR and co-regulation of androgen signaling remain unknown. Ongoing studies involve the characterization of these networks in prostate cancer cell lines, examining anchorage-independent capacity, invasion, migration, proliferation, and progression. Data collection and comparison will ascertain whether the signaling is driven by mutated AR, and the role of ARv7 will be elucidated through gene lockdown experiments. Citation Format: Alex L. McDonald, Spencer Snow, Shuk-mei Ho, Yuet-kin Leung. Novel androgen related gene network in prostate cancer cell model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6282.

Proteomics Analysis of the Interactome of N-myc Downstream Regulated Gene 1 and Its Interactions with the Androgen Response Program in Prostate Cancer Cells

Prognostic and Biological Role of the N-Myc Downstream-Regulated Gene Family in Hepatocellular Carcinoma.

Abstract #1185: Loss of N-myc Downstream-Regulated Gene 1 (NDRG1) Increases Prostate Cancer Cell Invasion by Upregulating CCL5

Ndrg3 Is An Androgen Regulated And Prostate Enriched Gene That Promotes In Vitro And In Vivo Prostate Cancer Cell Growth

N-myc Downstream Regulated Gene 1 Inhibition of Tumor Progression in Caco2 Cells.

NDR1/FBXO11 promotes phosphorylation-mediated ubiquitination of β-catenin to suppress metastasis in prostate cancer

NDRG2 Acts As a Negative Regulator Downstream of Androgen Receptor and Inhibits the Growth of Androgen-Dependent and Castration-Resistant Prostate Cancer

MiR-96-5p Induced NDRG1 Deficiency Promotes Prostate Cancer Migration and Invasion Through Regulating the NF-κB Signaling Pathway.

Prostate cancer invasion is promoted by the miR-96-5p-induced NDRG1 deficiency through NF-κB regulation

The Metastasis Suppressor, NDRG1, Modulates Β-Catenin Phosphorylation and Nuclear Translocation by Mechanisms Involving FRAT1 and PAK4

Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT

NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation

Discovery of a small-molecule NDR1 agonist for prostate cancer therapy

Abstract 6282: Novel androgen related gene network in prostate cancer cell model

Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer

Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells

Proteomics Analyses of Prostate Cancer Cells Reveal Cellular Pathways Associated with Androgen Resistance.

Promote of NDRG3 to the Growth and Drug Resistance of Prostate Cancer Cell

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma

Proteomic Comparison and MRM-Based Comparative Analysis of Metabolites Reveal Metabolic Shift in Human Prostate Cancer Cell Lines